$SNDX
Syndax Pharmaceuticals Inc

2022 Q4 Form 10-Q Financial Statement

#000095017022021848 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $12.38M
YoY Change -100.0% -100.0% 3165.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.19M $8.240M $6.801M
YoY Change 47.13% 21.16% 16.86%
% of Gross Profit
Research & Development $31.84M $26.90M $25.61M
YoY Change 33.23% 5.06% 77.72%
% of Gross Profit
Depreciation & Amortization $3.000K $8.000K $8.000K
YoY Change -70.0% 0.0% -60.0%
% of Gross Profit
Operating Expenses $42.03M $35.14M $32.41M
YoY Change 36.35% 8.44% 60.18%
Operating Profit -$35.14M -$20.03M
YoY Change 75.42% 0.9%
Interest Expense $2.945M $1.748M -$566.0K
YoY Change 2905.1% -408.83% 23.04%
% of Operating Profit
Other Income/Expense, Net -$106.0K -$262.0K -$41.00K
YoY Change -130.2% 539.02% -92.98%
Pretax Income -$39.19M -$35.40M -$20.64M
YoY Change -140.74% 71.53% 0.97%
Income Tax
% Of Pretax Income
Net Earnings -$39.19M -$35.40M -$20.64M
YoY Change -140.74% 71.53% 0.99%
Net Earnings / Revenue -166.78%
Basic Earnings Per Share -$0.58 -$0.40
Diluted Earnings Per Share -$0.62 -$0.58 -$397.2K
COMMON SHARES
Basic Shares Outstanding 60.22M 56.57M 51.96M
Diluted Shares Outstanding 60.67M 51.96M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $484.4M $350.7M $236.2M
YoY Change 8.41% 48.47% 34.44%
Cash & Equivalents $74.36M $71.38M $71.43M
Short-Term Investments $410.0M $279.3M $164.8M
Other Short-Term Assets $1.332M $1.974M $1.857M
YoY Change 17.15% 6.3% 32.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $489.8M $357.6M $238.3M
YoY Change 9.23% 50.11% 34.3%
LONG-TERM ASSETS
Property, Plant & Equipment $20.00K $23.00K $1.251M
YoY Change -92.81% -98.16% 108.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.469M
YoY Change
Other Assets $807.0K $881.0K $0.00
YoY Change -100.0%
Total Long-Term Assets $7.450M $2.056M $1.251M
YoY Change 490.8% 64.35% -34.16%
TOTAL ASSETS
Total Short-Term Assets $489.8M $357.6M $238.3M
Total Long-Term Assets $7.450M $2.056M $1.251M
Total Assets $497.2M $359.7M $239.5M
YoY Change 10.58% 50.18% 33.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.350M $7.115M $5.122M
YoY Change -23.27% 38.91% 34.79%
Accrued Expenses $24.71M $13.68M $14.10M
YoY Change 66.66% -2.96% 43.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000K $4.000K $9.489M
YoY Change -99.96%
Total Short-Term Liabilities $29.07M $20.80M $28.71M
YoY Change 40.53% -27.55% 88.89%
LONG-TERM LIABILITIES
Long-Term Debt $13.00K $14.00K $10.99M
YoY Change -99.93% -99.87% -45.06%
Other Long-Term Liabilities $709.0K $768.0K $798.0K
YoY Change -0.28% -3.76% -93.46%
Total Long-Term Liabilities $722.0K $782.0K $11.79M
YoY Change -96.5% -93.37% -63.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.07M $20.80M $28.71M
Total Long-Term Liabilities $722.0K $782.0K $11.79M
Total Liabilities $29.79M $21.59M $40.50M
YoY Change -27.86% -46.7% -14.38%
SHAREHOLDERS EQUITY
Retained Earnings -$693.0M -$653.8M
YoY Change 27.47%
Common Stock $1.161B $993.6M
YoY Change 21.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $467.4M $338.1M $199.0M
YoY Change
Total Liabilities & Shareholders Equity $497.2M $359.7M $239.5M
YoY Change 10.58% 50.18% 33.58%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$39.19M -$35.40M -$20.64M
YoY Change -140.74% 71.53% 0.99%
Depreciation, Depletion And Amortization $3.000K $8.000K $8.000K
YoY Change -70.0% 0.0% -60.0%
Cash From Operating Activities -$22.89M -$28.54M -$24.94M
YoY Change -122.73% 14.43% 36.31%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$137.6M -$6.793M $26.63M
YoY Change 130.04% -125.51% 38.13%
Cash From Investing Activities -$137.6M -$6.793M $26.63M
YoY Change 129.55% -125.51% 38.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 163.5M -13.53M 1.705M
YoY Change 48.94% -893.26% -3.67%
NET CHANGE
Cash From Operating Activities -22.89M -28.54M -24.94M
Cash From Investing Activities -137.6M -6.793M 26.63M
Cash From Financing Activities 163.5M -13.53M 1.705M
Net Change In Cash 2.979M -48.86M 3.392M
YoY Change -98.02% -1540.51% 23.35%
FREE CASH FLOW
Cash From Operating Activities -$22.89M -$28.54M -$24.94M
Capital Expenditures $0.00
Free Cash Flow -$22.89M
YoY Change -122.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37708
dei Entity Registrant Name
EntityRegistrantName
Syndax Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0162505
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
dei Entity Address Address Line1
EntityAddressAddressLine1
35 Gatehouse Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Building D
dei Entity Address Address Line3
EntityAddressAddressLine3
Floor 3
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-149000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
dei Entity Central Index Key
EntityCentralIndexKey
0001395937
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-11
dei Amendment Flag
AmendmentFlag
false
dei Local Phone Number
LocalPhoneNumber
419-1400
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
SNDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60223498
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71377000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221965000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
115000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
115000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
266461000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
217971000
CY2022Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
12870000
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
6894000
CY2022Q3 sndx Collaboration Receivable
CollaborationReceivable
4539000
CY2021Q4 sndx Collaboration Receivable
CollaborationReceivable
0
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2269000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1451000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
357631000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
448396000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
278000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1152000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
983000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
881000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q3 us-gaap Assets
Assets
359687000
CY2021Q4 us-gaap Assets
Assets
449657000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7115000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5669000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13213000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14465000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
471000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
361000
CY2022Q3 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
4000
CY2021Q4 sndx Current Portion Of Capital Lease
CurrentPortionOfCapitalLease
1000
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
187000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20803000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20683000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
768000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
711000
CY2022Q3 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
14000
CY2021Q4 sndx Capital Lease Less Current Portion
CapitalLeaseLessCurrentPortion
0
CY2022Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
0
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
19895000
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
782000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
20606000
CY2022Q3 us-gaap Liabilities
Liabilities
21585000
CY2021Q4 us-gaap Liabilities
Liabilities
41289000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60122661
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60122661
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54983105
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54983105
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
993547000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
952019000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1605000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
45000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-653846000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-543702000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
338102000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
408368000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
359687000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
449657000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12375000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13133000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12375000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13133000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26901000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25606000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86658000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64348000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8240000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6801000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23066000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18314000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
35141000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
32407000
us-gaap Operating Expenses
OperatingExpenses
109724000
us-gaap Operating Expenses
OperatingExpenses
82662000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-35141000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20032000
us-gaap Operating Income Loss
OperatingIncomeLoss
-109724000
us-gaap Operating Income Loss
OperatingIncomeLoss
-69529000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1748000
CY2021Q3 us-gaap Interest Expense
InterestExpense
649000
us-gaap Interest Expense
InterestExpense
3094000
us-gaap Interest Expense
InterestExpense
1906000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1781000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
83000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2884000
us-gaap Investment Income Interest
InvestmentIncomeInterest
312000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-295000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-210000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-262000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-607000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-420000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1743000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35403000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20639000
us-gaap Net Income Loss
NetIncomeLoss
-110144000
us-gaap Net Income Loss
NetIncomeLoss
-71272000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-270000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1650000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35673000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20645000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-111794000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71257000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35403000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20639000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-110144000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-71272000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60670294
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60670294
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51962320
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51962320
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59941384
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59941384
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51690173
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51690173
us-gaap Profit Loss
ProfitLoss
-110144000
us-gaap Profit Loss
ProfitLoss
-71272000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
30000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
33000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1357000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-473000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
309000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
302000
us-gaap Paid In Kind Interest
PaidInKindInterest
1103000
us-gaap Paid In Kind Interest
PaidInKindInterest
358000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
187000
us-gaap Share Based Compensation
ShareBasedCompensation
11778000
us-gaap Share Based Compensation
ShareBasedCompensation
9388000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7674000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1471000
sndx Increase Decrease In Collaboration Receivable
IncreaseDecreaseInCollaborationReceivable
-4539000
sndx Increase Decrease In Collaboration Receivable
IncreaseDecreaseInCollaborationReceivable
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1445000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1614000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13133000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1545000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2131000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-110781000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-71578000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
244467000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
189492000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
225000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
195683000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
208575000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48559000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19083000
us-gaap Payments For Proceeds From Deposit On Loan
PaymentsForProceedsFromDepositOnLoan
20998000
us-gaap Payments For Proceeds From Deposit On Loan
PaymentsForProceedsFromDepositOnLoan
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19427000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5131000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
260000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
242000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10063000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3312000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8752000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8685000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-150588000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-43810000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222080000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115358000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71492000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71548000
us-gaap Interest Paid Net
InterestPaidNet
2059000
us-gaap Interest Paid Net
InterestPaidNet
1499000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Syndax Pharmaceuticals, Inc. (“we,” “us,” “our” or the “Company”) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in 2005. We base our operations in Waltham, Massachusetts and we operate in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> segment.</span></p>
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.</span></p>
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51962320
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59941384
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59941384
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51690173
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51690173
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35403000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20639000
us-gaap Net Income Loss
NetIncomeLoss
-110144000
us-gaap Net Income Loss
NetIncomeLoss
-71272000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35403000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35403000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20639000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20639000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-110144000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-110144000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-71272000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-71272000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60670294
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60670294
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51962320
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3036719
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.00
CY2021Q1 sndx Number Of Pre Funded Warrants Exchanged For Common Stock
NumberOfPreFundedWarrantsExchangedForCommonStock
250000
CY2021Q4 sndx Number Of Pre Funded Warrants Cashless Exchanged For Common Stock
NumberOfPreFundedWarrantsCashlessExchangedForCommonStock
475784
CY2022Q3 sndx Number Of Pre Funded Warrants Exchanged For Common Stock
NumberOfPreFundedWarrantsExchangedForCommonStock
2832165
CY2022Q3 sndx Number Of Pre Funded Warrants Cashless Exchanged For Common Stock
NumberOfPreFundedWarrantsCashlessExchangedForCommonStock
2832151
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
187000
sndx Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue
-187000
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
278063000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1605000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
276458000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
343074000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
70000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
343119000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3381000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11778000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9388000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7778
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1167295
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10100000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
414809
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3300000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1157000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
642000
CY2022Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
410000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
429000
CY2022Q3 sndx Prepaid Subscriptions
PrepaidSubscriptions
298000
CY2021Q4 sndx Prepaid Subscriptions
PrepaidSubscriptions
230000
CY2022Q3 sndx Prepaid Conference Meeting Costs
PrepaidConferenceMeetingCosts
252000
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
152000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
150000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2269000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1451000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20639000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
199004000
CY2022Q3 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
5297000
CY2021Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
7760000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3998000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4342000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
732000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
662000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3186000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1701000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13213000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14465000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
374549000
CY2022Q2 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
19427000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3938000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2022Q2 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
58000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2235000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37572000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
361940000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4362000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3381000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11778000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9388000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4362000
sndx Prepayment Fee
PrepaymentFee
400000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
408368000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3478000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-685000
CY2022Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
92000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37169000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4362000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-270000
CY2022Q3 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
110000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7363000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35403000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
338102000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
252188000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2767000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2021Q1 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
79000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
881000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-27723000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
228205000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3240000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2021Q2 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
64000
CY2021Q2 sndx Stock Issued During Period Value At The Market Offering Expenses
StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
200000
CY2021Q2 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
5131000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
825000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22910000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
214563000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3381000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2021Q3 sndx Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
AdjustmentToAdditionalPaidInCapitalEmployeeWithholdingsEmployeeStockPurchasePlan
99000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1606000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-22-021848-index-headers.html Edgar Link pending
0000950170-22-021848-index.html Edgar Link pending
0000950170-22-021848.txt Edgar Link pending
0000950170-22-021848-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-20220930.htm Edgar Link pending
sndx-20220930.xsd Edgar Link pending
sndx-ex31_1.htm Edgar Link pending
sndx-ex31_2.htm Edgar Link pending
sndx-ex32_1.htm Edgar Link pending
sndx-20220930_cal.xml Edgar Link unprocessable
sndx-20220930_def.xml Edgar Link unprocessable
sndx-20220930_pre.xml Edgar Link unprocessable
sndx-20220930_lab.xml Edgar Link unprocessable
sndx-20220930_htm.xml Edgar Link completed